Published on Roswell Park Cancer Institute (http://www.roswellpark.org)

Professor of Oncology
Chief, Genitourinary Section
Leader, Genitourinary Program, Department of Medicine
Roswell Park Cancer Institute
Adjunct Associate Professor of Oncology and Urology
The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University
Profile
Areas of Expertise: 
Bladder Cancer
Kidney Cancer
Prostate Cancer
Research
Research Interests: 
Understanding the mechanisms of angiogenesis and epigenetics in the progression of cancer
Phase I and phase II clinical trials of novel agents for treatment of genitourinary cancers
Drug development for genitourinary malignancies: combination strategies with chromatin remodeling agents, antiangiogenics and immunotherapies
Background Information
Education and Training: 
MD - Catholic University School of Medicine, Rome, Italy
Residency: 
Catholic University, Rome, Italy
Montefiore Medical Center, Bronx, NY
Board Certification: 
Diplomate, Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowships: 
University of South Florida, Tampa, FL
National Institute on Aging, National Institutes of Health, Bethesda, MD
Johns Hopkins University, Baltimore, MD
Publications
Publications: 
  • Hammers HJ, Netto G, Teh BT, Furge K, Dykema K, Paesante S, Shen L, Ellis L, Shah P, Jaspers J, Rudek M, Sharma R, Salumbides B, Verheul HM, Pili R. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Molecular cancer therapeutics 2010; 9(6):1525-1535
  • Koskimaki JE, Karagiannis ED, Tang BC, Hammers H, Watkins DN, Pili R, Popel AS. Pentastatin-1, a collagen IV derived 20-mer peptide, suppresses tumor growth in a small cell lung cancer xenograft model. BMC cancer 2010; 10 :29
  • Pili R, Wong S, Leach J, Goel S, Dreicer R, Srinivas S, Van Hazel G, Mainwaring PN, Rosenthal MA, Clingan P. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clinical cancer research 2010; 16(10):2906-2914
  • Verheul HMW, van Erp K, Homs MYV, Yoon GS, van Der Groep P, Rogers C, Hansel DE, Netto GJ, Pili R. The relationship of vascular endothelial growth factor and coagulation factor (fibrin and fibrinogen) expression in clear cell renal cell carcinoma. Urology 2010; 75(3):608-614
  • Ellis L, Pili R. Histone deacetylase inhibitors: Advancing therapeutic strategies in hematological and solid malignancies. Pharmaceuticals (Basel, Switzerland) 2010; 3(8):2441-2469
  • Shen Li, Pili R. The histone deacetylase (HDAC) inhibitor SNDX-275 enhances the antitumor effect of interleukin 2 (IL-2) by suppressing regulatory T cell gene expression and function. Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:1318
  • Pettazzoni P, Barrera G, Dianzani MU, Ciamporcero E, Atadja P, Ellis L, Minelli R, Wang D, Liu S, Tagliavacca L, Sotomayor P, Toaldo C, Pizzimenti S, Pili R. Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells. Free radical biology and medicine 2011; 50(2):313-322
  • Snyder CF, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30. Quality of life research 2010; 19(6):837-845
  • Keizman D, Sinibaldi VJ, Carducci MA, Denmeade SR, Drake CG, Pili R, Hudock S, Zahurak M, Eisenberger MA. Dose-dependent changes in PSA dynamics with 25 mg/day versus 5 mg/day of lenalidomide (Len) treatment (Rx) in patients (pts) with biochemically relapsed prostate cancer (BRPC) (M0): A double-blinded randomized phase I/II study : 2010 Genitourinary Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #207
  • Pili R, Lodge M, Verheul H, Mashtare T, Wahl RL, Martin JE, Espinoza-Delgado I, Liu G, Carducci MA. Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in pretreated patients with renal cell carcinoma: Safety, efficacy, and pharmacodynamic results : 2010 Genitourinary Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #350
  • Motzer RJ, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Kuzel TM, Kessinger A, Jonasch E, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7(6):618-630
  • Motzer RJ, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Kuzel TM, Kessinger A, Jonasch E, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Wang J. NCCN clinical practice guidelines in oncology: testicular cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7(6):672-693
  • Pili R. Recent investigations of histone deacetylase inhibitors in renal cell carcinoma. Clinical advances in hematology and oncology : H&O 2009; 7(4):252-254
  • Tamaskar I, Pili R. Update on novel agents in renal cell carcinoma. Expert review of anticancer therapy 2009; 9(12):1817-1827
  • Pili R. Is this a true renaissance for the treatment of prostate cancer?. Oncology (Williston Park, N.Y.) 2010; 24(14):1327-1328
  • Keizman D, Hudock S, Antonarakis ES, Pili R, Drake C, Denmeade S, Carducci M, Sinibaldi V, Zahurak M, Eisenberger M. Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. Clinical cancer research 2010; 16(21):5269-5276
  • Resta LP, Carducci MA, Boinpally R, Franke A, Porter J, King S, Spitz A, Eisenberger MA, Pili R, Sweeney CJ. A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. Cancer chemotherapy and pharmacology 2011; 67(2):431-438
  • George S, Pili R, Carducci MA, Kim JJ. Role of immunotherapy for renal cell cancer in 2011. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(9):1011-1018
  • O'Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W 3rd, Pili R, Schwaab T. Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible? . Urology 2011; 78(3):595-600
  • Pettazzoni P, Pili R, Dianzani MU, Uchida K, Minelli R, Toaldo C, Minero VG, Dal Bello F, Pizzimenti S, Medana C, Ciamporcero E, Barrera G. Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells. Free radical biology and medicine 2011; 51(8):1610-1618
  • Schwaab T, Pili R. Provenge: combating prostate cancer with a vengeance? . Expert review of vaccines 2011; 10(8):1113-1114
  • Harrison MR, Hahn NM, Pili R, Oh WK, Hammers H, Sweeney C, Kim K, Perlman S, Arnott J, Sidor C, Wilding G, Liu G. A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal(R) dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC). Investigational new drugs 2011; 29(6):1465-1474
  • Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pill R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(9):960-977
  • Goldman JW, Gordon MS, Hurwitz H, Pili R, Mendelson DS, Adams BJ, Alvarez D, Seon BK, Theuer CP, Leigh BR, Rosen LS. A phase I study of TRC105 (anti-CD105 antibody) in patients with advanced solid tumors : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3073
  • Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Hammers HJ, Carducci MA. Effect of angiotenstin system inhibitors (ASIs) on the outcome of sunitinib treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC) : 2011 Genitourinary Cancers Symposium. Journal of clinical oncology 2011; 29(7 Suppl.):317
  • Pili R, Qin R, Flynn PJ, Picus J, Millward M, Ho WM, Pitot HC, Tan W, Erlichman C, Vaishampayan UN. MC0553: A phase II safety and efficacy study with the VEGF receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer : 2011 Genitourinary Cancers Symposium. Journal of clinical oncology 2011; 29(7 Suppl.):259
  • Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Nordle O, Forsberg G, Carducci MA, Pili R. Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups : 2011 Genitourinary Cancers Symposium. Journal of clinical oncology 2011; 29(7 Suppl.):126
  • Harrison MR, Pili R, Logan T, Wilding G, Eickhoff J, Sidor C, Staab M, Arnott J, Liu G. Phase II study of 2-methoxyestradiol NanoCrystal dispersion (2ME2) alone and in combination with sunitinib (SU) in patients with metastatic renal cell carcinoma (mRCC) progressing on SU. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e16116
  • Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Journal of clinical oncology 2009; 27(22):3584-3590
  • Huang P, Carducci MA, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers HJ, Keizman D. The association of pretreatment (pre-tx) neutrophil to lymphocyte ratio (NLR) with outcome of sunitinib tx in patients (pts) with metastatic renal cell carcinoma (mRCC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):4621
  • Kim JJ, Huang P, Eisenberger MA, Pili R, Antonarakis ES, Hammers HJ, Carducci MA, Keizman D. The role of angiotensin system inhibitors (ASIs) in the outcome of sunitinib treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e15008
  • Ellis, L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. PloS one 2011; 6(11):e27178
  • Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, Griffioen AW, Assaraf YG, Pili R, Peters GJ, Verheul HM. Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance. Clinical cancer research 2011; 17(23):7337-7346
  • Pili R, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Bjork A, Nordle O, Forsberg G, Carducci MA, Armstrong AJ. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. Journal of clinical oncology 2011; 29(30):4022-4028
  • Ellis L, Lehet K, Ramakrishnan S, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Concurrent Histone Deacetylase and Mammalian Target of Rapamycin Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated With Alterations in MicroRNA Expression. European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S501
  • Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009; 115(23):5541-5549
  • Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer letters 2009; 280(2):145-153
  • Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(Suppl. 1):S1-S29
  • Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. European journal of cancer (Oxford, England : 1990) 2011; 47(13):1955-1961
  • Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. European journal of cancer (Oxford, England : 1990) 2012; 48(2):202-208
  • Kolmakova A, Rajesh M, Zang D, Pili R, Chatterjee S. VEGF recruits lactosylceramide to induce endothelial cell adhesion molecule expression and angiogenesis in vitro and in vivo. Glycoconjugate journal 2009; 26(5):547-558
  • Pili R, Salumbides B, Zhao M, Altiok S, Qian D, Zwiebel J, Carducci MA, Rudek MA. Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours. British journal of cancer 2012; 106(1):77-84
  • Snyder CF, Garrett-Mayer E, Blackford AL, Brahmer JR, Carducci MA, Pili R, Stearns V, Wolff AC, Dy SM, Wu AW. Concordance of cancer patients' function, symptoms, and supportive care needs. Quality of life research 2009; 18(8):991-998
  • Vaughn DJ, Srinivas S, Stadler WM, Pili R, Petrylak D, Sternberg CN, Smith DC, Ringuette S, De Wit E, Pautret V, George C. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study. Cancer 2009; 115(18):4110-4117
  • Bruce JY, Eickhoff J, Pili R, Logan T, Carducci M, Arnott J, Treston A, Wilding G, Liu G. A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Investigational new drugs 2012; 30(2):794-802
  • Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R. Development of a castrate resistant transplant tumor model of prostate cancer. Prostate 2012; 72(6):587-591
  • Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Molecular cancer therapeutics 2012; 11(2):383-392
  • Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PloS one 2012; 7(1):e30815
  • Tamaskar I, Dhillon J, Pili R. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clinical advances in hematology and oncology : H&O 2011; 9(2):101-110
  • Wang ES, Pili R, Seshadri M. Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule. Journal of clinical oncology 2012; 30(7):760-761
  • Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Assaraf YG, Pili R, Peters GJ, Verheul HMW. Lysosomal sequestration of sunitinib may play a role in its resistance. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #2852
  • Minelli R, Cavalli R, Fantozzi R, Dianzani C, Pettazzoni P, Ellis L, Shen L, Pili R. Antitumor activity of nanosponge-encapsulated camptotechin in human prostate tumors. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #4431
  • Paesante S, Miles MK, Nguyen H, Vessella R, Pili R. Targeting the Akt pathway and HDAC signaling in prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #3504
  • Shen L, Ciesielski M, Ellis L, Fenstermaker R, Pili R. Selective class I HDAC inhibitor SNDX-275 enhances anti-tumor survivin vaccine therapy by suppressing regulatory T cells in a model of prostate cancer. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1792
  • Hammers HJ, Verheul H, Salumbides B, Sharma R, Jaspers J, Rudek M, Netto G, Pili R. Epithelial to mesenchymal transition is associated with acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study . Proceedings of the American Association for Cancer Research Annual Meeting 2010; 51:Abstract #388
  • Armstrong AJ, Gingrich JR, Haggman M, Stadler WM, Damber JE, Belkoff L, Clark R, Brosman S, Nordle O, Forsberg G, Carducci MA, Pili R. Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer. European urology supplements 2012; 11(1):E126-U515
  • Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. European journal of cancer (Oxford, England : 1990) 2012; 48(7):1031-1037
  • Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular cancer. Journal of the National Comprehensive Cancer Network : JNCCN 2012; 10(4):502-535
  • Armstrong AJ, Haggman M, Stadler WM, Gingrich JR, Assikis VJ, Polikoff J, Denmeade SR, George DJ, Andreou C, Clark WR, Sieber P, Agajanian R, Belkoff L, Damber J-E, Nordle O, Forsberg G, Carducci MA, Pili R. Tasquinimod and survival in men with metastatic castration-resistant prostate cancer: Results of long-term follow-up of a randomized phase II placebo-controlled trial. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4550
  • Berger R, Keizman D, Ish-Shalom M, Hammers HJ, Eisenberger MA, Sinibaldi VJ, Pili R, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Carducci MA. Influence of risk factors for renal cell carcinoma (RCC) on outcome of patients (pts) with metastatic disease (mRCC) treated with sunitinib (Su). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e15058
  • George S, Choi K-S, Pili R, Kazim AL. The lipid metabolome of clear cell renal cell carcinoma (CCRCC). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #10609
  • Kossoff E, Batty N, Ceacareanu AC, Attwood K, Miller D, Rabey J, Lee C, Ahmad A, Ebos JM, Schwaab T, George S, Pili R. Evaluation of parameters for treatment duration of sunitinib in metastatic renal cell carcinoma. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e15042
  • Peer A, Ish-Shalom M, Hammers HJ, Eisenberger MA, Sinibaldi VJ, Pili R, Maimon N, Gottfried M, Hayat H, Kovel S, Sella A, Neumann A, Boursi B, Berger R, Carducci MA, Keizman D. Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4619
  • Pili R, Shen L, George S, Hammers H, Sandecki A, Collins C, Espinoza-Delgado I, Carducci MA. Phase I/II study of high-dose interleukin 2, aldesleukin, in combination with the histone deacetylase inhibitor entinostat in patients with metastatic renal cell carcinoma. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #TPS4687
  • Keizman D, Ish-Shalom M, Taksey JD, Pili R, Hammers HJ, Eisenberger MA, Boursi B, Berger R, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Carducci MA. Effect of bisphosphonates (Bis) combined with sunitinib (Su) on the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC) : 2012 Genitourinary Cancers Symposium. Journal of clinical oncology 2012; 30(5 Suppl.):Abstract #379
  • Kotowski AS, Stegemann A, Rehman S, Attwood K, Levine EG, Guru K, Trump DL, Pili R. A single-center experience of chemotherapy for muscle-invasive bladder cancer after radical cystectomy : 2012 Genitourinary Cancers Symposium. Journal of clinical oncology 2012; 30(5 Suppl.):Abstract #318
  • Montgomery RB, Eisenberger MA, Rettig M, Chu F, Pili R, Stephenson J, Vogelzang NJ, Morrison J, Taplin M-E. Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4665
  • Ebos JM, Pili R. Mind the gap: potential for rebounds during antiangiogenic treatment breaks. Clinical cancer research 2012; 18(14):3719-3721
  • Minelli R, Cavalli R, Ellis L, Pettazzoni P, Trotta F, Ciamporcero E, Barrera G, Fantozzi R, Dianzani C, Pili R. Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells. European journal of pharmaceutical sciences 2012; 47(4):686-694
  • Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer chemotherapy and pharmacology 2012; 70(2):305-313
  • Batty N, Kossoff E, Pili R. Immunotherapy in prostate cancer: Focus on sipuleucel-T. International journal of targeted therapies in cancer 2012; September:32-39
  • Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI, Carducci MA. A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Annals of oncology 2012; 23(10):2714-2719
  • Chintala S, Najrana T, Toth K, Cao S, Durrani FA, Pili R, Rustum YM. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition. BMC cancer 2012; 12 :293
  • Tolcher AW, Chi KN, Shore ND, Pili R, Molina A, Acharya M, Kheoh T, Jiao JJ, Gonzalez M, Trinh A, Pankras C, Tran N. Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer chemotherapy and pharmacology 2012; 70(2):305-313
Referral
Email: 
Roberto.Pili@RoswellPark.org
Fax: 
716-845-8232
Source URL (retrieved on 05/25/2013 - 11:32pm): http://www.roswellpark.org/roberto-pili